SCORE Analyzer for the Objective Screening of Risk of Corneal Ectasia from Bausch + Lomb Technolas Receives CE Mark

FOR RELEASE THURSDAY, APRIL 3, 2014

MUNICH, GERMANY — Bausch + Lomb, the global eye health company, announced today that its SCORE Analyzer for the objective screening of the risk of corneal ectasia received CE mark in the European Union.¹-⁵ Bausch + Lomb Technolas (TECHNOLAS Perfect Vision GmbH – A Bausch + Lomb Company), is a leader in the field of ophthalmic laser and diagnostic platforms, and the SCORE Analyzer provides an important new diagnostic tool in refractive surgery.

The SCORE software algorithm* was developed by Dr Damien Gatinel and Dr Alain Saad, of the Rothschild Foundation, Paris, who compared the data for corneas with no risk of ectasia against data for a group of early subclinical (and placido-negative) keratoconus eyes with significant keratoconus in the contralateral eye. In association with Bausch + Lomb Technolas, the SCORE algorithm was developed to use data coming from the ORBSCAN® IIz Topographer, using Slit scanning and Placido based technology.

The SCORE Analyzer provides the surgeon an accurate and simple objective evaluation tool for early stage keratoconus. By taking one examination with the ORBSCAN, the SCORE software automatically associates the placido-based keratometric map, anterior and posterior corneal elevation and corneal thickness profile into one single value or SCORE.

“SCORE is a screening tool that automatically associates the main parameters contributing to development of early stage keratoconus into a single number (SCORE) classification system,” said Kristian Hohla, Ph.D., President of Bausch + Lomb Technolas, Chairman of Laser and Surgical Strategy and Development. He continued “This single SCORE value is immediate and simple to interpret.”

Dr Gatinel said “The SCORE Analyzer helps the surgeon to decide whether LASIK or PRK surgery might be contraindicated. This new diagnostic tool will provide additional reassurance for both surgeons and patients.”

*The algorithm was developed based on data from a patient group with myopic eyes and younger than 50 years. SCORE is not approved for use in the US.

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments. We globally develop, manufacture and market one of the most comprehensive product portfolios in our industry, which are available in more than 100 countries.

References:

News Media Contacts:

Lindsay Brooks
Medical Communications, Bausch + Lomb Technolas
+44 7825 769007 (mobile) or lindsay.brooks@bausch.com